Sign in
Taking people in United StatesNo phase

Tests glucose sensor monitoring for type 2 diabetes during pregnancy

Compares a continuous glucose sensor with fingerstick checks in pregnant women with type 2 diabetes.

Key facts

Who runs it
University of Alabama at Birmingham
Where
Birmingham, Chapel Hill, Greenville, Houston, Philadelphia, Portland, and San Diego, United StatesSee the 7 sites
Trial code
Registry title
CGM for Management of Type 2 Diabetes in Pregnancy
Status
Recruiting
People taking part
564 people, planned
Started
8 Apr 2025
Expected to end
Jul 2029
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • CGM
Record updated
29 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women aged 18-50 who have type 2 diabetes and are 6 to less than 23 weeks pregnant.

Age
18 to 50 years
Sex
Women only
Disease stage
Type 2 diabetes treated with daily insulin injections or diabetes pills, diagnosed before pregnancy or before 14 weeks of pregnancy with hemoglobin A1c 6.5% (48 mmol/mol) or greater. Pregnant with a viable fetus at 6 to less than 23 weeks.
Biomarker or test result
Hemoglobin A1c 6.5% (48 mmol/mol) or greater for diabetes diagnosed before 14 weeks of pregnancy.

Main reasons for not taking part

  • Cannot or will not wear a continuous glucose monitor because of adhesive intolerance or skin conditions
  • Twins or more (multiple gestation)
  • Major fetal anomaly or two or more minor fetal anomalies
  • Planned delivery outside the study consortium
  • Took part in this trial in a previous pregnancy

This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant with viable fetus at 6 to less than 23 weeks gestation

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater
  • Pregnant with viable fetus at 6 to less than 23 weeks gestation
  • Maternal age 18-50 years old

Who cannot take part

  • Participation in this trial in a previous pregnancy
  • Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions
  • Multiple gestation
  • Major fetal anomaly or two or more minor fetal anomalies
  • Planned delivery outside study consortium
  • Participating in another conflicting interventional study
  • Patient unable to consent
  • Physician refusal for other reasons

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 50 years old?

Where in United States

  • University of Alabama at BirminghamBirmingham, United StatesContact: Ashley BattarbeeTaking people
  • University of North Carolina, Chapel HillChapel Hill, United StatesContact: Kim Boggess, MDTaking people
  • Prisma Health Greenville Memorial HospitalGreenville, United StatesContact: Daniel Pasko, MDTaking people
  • University of Texas Health Science Center at HoustonHouston, United StatesContact: Michal Fishel Bartal, MDTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Celeste Durnwald, MDTaking people
  • Oregon Health and Science UniversityPortland, United StatesContact: Amy Valent, DO, MCRTaking people
  • University of California At San DiegoSan Diego, United StatesContact: Gladys Ramos, MDTaking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:

Read full original descriptionShow less

1. Does continuous glucose monitoring improve infant outcomes compared to self-monitoring of blood glucose? 2. Does continuous glucose monitoring improve maternal diabetes control and other maternal outcomes compared to self-monitoring of blood glucose? 3. What other factors increase the risk of maternal and infant complications?

Participants will:

1. Use continuous glucose monitoring or self-monitoring of blood glucose to monitor blood sugar control from enrollment until delivery 2. Have blood drawn at enrollment, 24 weeks, 34 weeks and delivery to measure hemoglobin A1c levels and store blood for future analysis 3. Complete surveys about social support, environmental stressors, diabetes distress and glucose monitoring satisfaction at research visits 4. Have umbilical cord blood collected at delivery for analysis

The 2 groups in the trial

  • Continuous Glucose MonitoringTreatment being tested

    Real-time continuous glucose monitoring

    Treatment: CGM

  • Self-Monitoring of Blood GlucoseNo study treatment, for comparison

    Self-monitoring of blood glucose (standard of care)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy
Plain-language title
Tests glucose sensor monitoring for type 2 diabetes during pregnancyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT06628453, who can take part
Record updated
29 June 2026